Assets
(39 total)
39Total Assets
17Approved
9Phase 3 / Filed
13Phase 1–2 / Early
27Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis Ulcerative Colitis, Crohn's Disease | |
Afatinib(Gilotrif) | Approved | EGFR/HER1, HER2, HER4Small molecule | Non-Small Cell Lung Cancer |
Empagliflozin(Jardiance) | Approved | SGLT2Small molecule | Type 2 DiabetesHeart FailureChronic Kidney DiseaseAtherosclerotic Cardiovascular Disease |
| Approved | Insulin receptor (basal)Peptide | Type 2 DiabetesType 1 Diabetes | |
| Approved | Muscarinic acetylcholine receptor (M3)Small molecule | Chronic Obstructive Pulmonary DiseaseAsthma | |
| Approved | Muscarinic M3 receptor / Beta-2 adrenergic receptor (combination)Small molecule | Chronic Obstructive Pulmonary Disease | |
Linagliptin(Tradjenta) | Approved | DPP-4Small molecule | Type 2 Diabetes |
| Approved | PDE4BSmall molecule | Idiopathic Pulmonary FibrosisSystemic Sclerosis | |
| Approved | Triple angiokinase inhibitor (VEGFR/FGFR/PDGFR)Small molecule | Idiopathic Pulmonary FibrosisSystemic Sclerosis | |
| Approved | Beta-2 adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary Disease | |
| Approved | Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary Disease | |
| Approved | Dopamine D2 / D3 receptorsSmall molecule | Parkinson's Disease | |
risankizumab(Skyrizi) | Approved | IL-23 p19Monoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease |
spesolimab(Spevigo) | Approved | IL-36 receptorMonoclonal antibody | PsoriasisHidradenitis Suppurativa |
| Approved | Muscarinic acetylcholine receptor (M3)Small molecule | Chronic Obstructive Pulmonary DiseaseAsthma |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(53 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
2027 (13)
March 2027 (2)
April 2027 (3)
Nerandomilast (Jascayd)Phase 3Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Est. primary completion 2027-04-15 · NCT06806592 · CT.gov ↗
What to watch
Est. primary completion 2027-04-16 · NCT07107945 · CT.gov ↗
What to watch
Est. primary completion 2027-04-28 · NCT06238622 · CT.gov ↗
What to watch
June 2027 (1)
Est. primary completion 2027-06-26 · NCT07662122 · CT.gov ↗
What to watch
July 2027 (1)
Est. primary completion 2027-07-30 · NCT06636656 · CT.gov ↗
What to watch
August 2027 (2)
September 2027 (1)
Est. primary completion 2027-09-30 · NCT03886246 · CT.gov ↗
What to watch
November 2027 (1)
Est. primary completion 2027-11-12 · NCT06624670 · CT.gov ↗
What to watch
December 2027 (2)
ObrixtamigPhase 2Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Est. primary completion 2027-12-17 · NCT05882058 · CT.gov ↗
What to watch
Est. primary completion 2027-12-31 · NCT06166836 · CT.gov ↗
What to watch
2028 (14)
January 2028 (2)
Est. primary completion 2028-01-17 · NCT07754461 · CT.gov ↗
What to watch
February 2028 (1)
Est. primary completion 2028-02 · NCT04524611 · CT.gov ↗
What to watch
March 2028 (1)
Est. primary completion 2028-03-01 · NCT06962839 · CT.gov ↗
What to watch
April 2028 (1)
Est. primary completion 2028-04 · NCT04862286 · CT.gov ↗
What to watch
May 2028 (1)
Est. primary completion 2028-05-22 · NCT06424288 · CT.gov ↗
What to watch
July 2028 (2)
Est. primary completion 2028-07-03 · NCT07929051 · CT.gov ↗
What to watch
September 2028 (3)
November 2028 (1)
Est. primary completion 2028-11-30 · NCT06581432 · CT.gov ↗
What to watch
December 2028 (2)
Est. primary completion 2028-12-05 · NCT07540988 · CT.gov ↗
What to watch
2029 (13)
January 2029 (1)
Zongertinib · HernexeosPhase 1/2Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma …
Est. primary completion 2029-01-08 · NCT06324357 · CT.gov ↗
What to watch
February 2029 (3)
April 2029 (3)
May 2029 (1)
Nerandomilast (Jascayd)Phase 3Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
Est. primary completion 2029-05-14 · NCT07201922 · CT.gov ↗
What to watch
June 2029 (1)
Est. primary completion 2029-06-05 · NCT06632457 · CT.gov ↗
What to watch
August 2029 (1)
Est. primary completion 2029-08 · NCT06865105 · CT.gov ↗
What to watch
November 2029 (1)
2030 (5)
January 2030 (1)
Est. primary completion 2030-01 · NCT06548542 · CT.gov ↗
What to watch
February 2030 (1)
Est. primary completion 2030-02-26 · NCT07497087 · CT.gov ↗
What to watch
March 2030 (1)
Est. primary completion 2030-03-21 · NCT07789015 · CT.gov ↗
What to watch
April 2030 (2)
Est. primary completion 2030-04-17 · NCT07843940 · CT.gov ↗
What to watch
ObrixtamigPhase 1/2Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology …
Est. primary completion 2030-04-26 · NCT07707895 · CT.gov ↗
What to watch
2031 (3)
2032 (1)
February 2032 (1)
Est. primary completion 2032-02-26 · NCT07195695 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Est. primary completion 2034-07 · NCT07071519 · CT.gov ↗
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
US, FDA · Source ↗
Boehringer Ingelheim · Source ↗
September 2026Topline resultVicadrostatEASi-KIDNEY (NCT06531824) Phase 3 stopped on DMC recommendation for lack of expected benefit
Boehringer Ingelheim · Source ↗
Boehringer Ingelheim · Source ↗
9 January 2023WithdrawalPramipexoleFDA withdraws approval of NDA 020667 (Federal Register 2022-26661)
US, FDA · Source ↗
Financial reports
No financial reports recorded.